Key facts
- Notable investors include Transpose Platform Management, Entrepreneurs First.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Pharosyn
- ·The full record, as it builds
Funding rounds
No funding rounds for Pharosyn are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pharosyn
Developer of an AI-powered competitive intelligence platform designed to monitor and analyze biopharma data for strategic decision-making. The company offers continuous tracking of clinical, regulatory, and commercial data sources, automated generation of pipeline-specific strategic reports, and event prioritization capabilities, enabling pharmaceutical and biotechnology teams to maintain competitor visibility and support ongoing planning.
- Sector
- Information Technology
- Founded
- 2025
- Employees
- 2
- Website
- pharosyn.ai/
- Ownership
- Privately Held (backing)
Pharosyn doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pharosyn shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pharosyn in its N-PORT filings yet. We sweep new filings monthly.